


PHARMACEUTICAL 2023

Eledon Pharmaceuticals Inc. Rank 194 of 446









PHARMACEUTICAL 2023



Eledon Pharmaceuticals Inc. Rank 194 of 446

The relative strengths and weaknesses of Eledon Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Eledon Pharmaceuticals Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 73% points. The greatest weakness of Eledon Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 89% points.

The company's Economic Capital Ratio, given in the ranking table, is 112%, being 69% points above the market average of 43%.

| Input Variable | Value in 1000 USD |
|---|----------------------|
| Assets, Current | 59,518 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 6,475 |
| Liabilities, Non-Current | 383 |
| Other Assets | 33,275 |
| Other Compr. Net Income | 0 |
| Other Expenses | 48,648 |
| Other Liabilities | 1,752 |
| Other Net Income | 462 |
| Other Revenues | 0 |
| Property and Equipment | 0 |
| Research and Development | 27,080 |
| Selling, General and Administrative Expense | 12,700 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Assets | 92,793 |
| Liabilities | 8,610 |
| Expenses | 88,428 |
| Revenues | 0 |
| Stockholders Equity | 84,183 |
| Net Income | -87,966 |
| Comprehensive Net Income | -87,966 |
| Economic Capital Ratio | 112% |

